Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Early Stage Breast Cancer Clear all
Active, not recruiting Phase 2 Interventional

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

NCT05949021
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
Combination of liposomal doxorubicin
Drug
Lead sponsor
Mridula George, MD
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Not applicable Interventional Results available

Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer

NCT00182728
View directory record Official record
Conditions
Breast Cancer
Interventions
surgery, therapy, radiation therapy
Procedure · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
48 Years to 120 Years · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 30, 2026, 4:28 PM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

NCT05069038
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib 125mg
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

NCT07743190
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
Interventions
Carboplatin, Paclitaxcel, Pembrolizumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
2
States / cities
Syracuse, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty

NCT01553097
View directory record Official record
Conditions
Breast Cancer, Neurocognitive Impairment, Quality of Life
Interventions
Neurocognitive impairment observation
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Phase 2 Interventional

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

NCT06245889
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Olaparib, Capecitabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Terminated No phase listed Observational

Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)

NCT02364960
View directory record Official record
Conditions
Early Stage Breast Cancer, Neoplasm of the Breast, Breast Tumor
Interventions
Not listed
Lead sponsor
TriHealth Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Not applicable Interventional

A Study of High-Dose Vit D Versus Standard of Care Vit D Supplementation

NCT05016310
View directory record Official record
Conditions
Breast, Breast Cancer, Osteoporosis
Interventions
High Dose Vitamin D, Standard of Care Vitamin D
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

NCT03112590
View directory record Official record
Conditions
Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
Interventions
Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab, Pertuzumab, Post Therapy Surgery
Biological · Drug · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 30, 2026, 4:28 PM EDT
Terminated Not applicable Interventional Results available

Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer

NCT03648983
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
arm circumference measurement, Bioimpedance spectroscopy
Procedure · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Phase 2 Interventional

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

NCT01766297
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Interventions
Proton Radiotherapy
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
50 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2035
U.S. locations
9
States / cities
Scottsdale, Arizona • San Diego, California • Warrenville, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Phase 2 Interventional

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

NCT01042379
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions
Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
42
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed No phase listed Observational

PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer

NCT00362973
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, needle biopsy, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18
Other · Procedure · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 120 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Not applicable Interventional

Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer

NCT07630402
View directory record Official record
Conditions
Breast Cancer With Low to Intermediate HER2 Expression
Interventions
Echocardiogram
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 79 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 2 Interventional

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

NCT00003269
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide
Biological · Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 1Phase 2 Interventional

Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.

NCT00405678
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Training, Chemo only
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

NCT03433313
View directory record Official record
Conditions
Breast Cancer
Interventions
EG12014, Herceptin
Drug
Lead sponsor
EirGenix, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Farmington Hills, Michigan • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 30, 2026, 4:28 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Recruiting Not applicable Interventional

Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy

NCT07386444
View directory record Official record
Conditions
Early Stage Breast Carcinoma, Dyspnea
Interventions
Inspiratory muscle training
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299
View directory record Official record
Conditions
Triple Negative Breast Cancer, PD-L1 Negative
Interventions
Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
130
States / cities
Tucson, Arizona • Burbank, California • La Jolla, California + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Active, not recruiting Not applicable Interventional

The Active After Cancer Trial (AACT)

NCT00548236
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Telephone-Based exercise intervention
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
9
States / cities
La Jolla, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 30, 2026, 4:28 PM EDT
Completed No phase listed Observational

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

NCT00874211
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
assessment of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
3,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
451
States / cities
Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 30, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

NCT02273973
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo, Taselisib
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 30, 2026, 4:28 PM EDT